Impaired renal function in patients with degenerative distrophic diseases of the spine and axial spondyloarthritis receiving non-steroidal anti-inflammatory drugs


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Aim. Determination of the nature and severity of kidney damage in persons with different etiology of chronic back pain receiving a comparable total dose of NSAIDs. Materials and Methods. The study included 67 patients with chronic back pain of different genesis (44 patients with axial spondylarthritis (ax-SpA) and 23 patients with degenerative-dystrophic diseases of the spine (DDDS)) receiving NSAIDs in comparable dosages. Patients underwent assessment of glomerular filtration rate according to CKD-Ері and markers of renal damage (albuminuria and globulinuria, urine enzymes). Results. In patients with ax-SpA, mean GFR was 95.0 [84.0; і02.0] ml/min/1.73 m2, in patients with DDDS, mean GFR was 77.5 [70.0; 89.0] ml/min/1.73 m2 (p=0.0003). The urine albumin level in patients with ax-SpA was 36.74 [25.06; 46.7] mg/g, in patients with DDDS - 73.08 [40.68; і20.76] mg/g (p=0.002); the α1-microglobulin level in patients with ax-SpA was 23.4 [18.24; 32.06] mg/g, in PATIENTS with DDDS - 161.66 [121.04; 225.78] mg/g, P=0.0000. Conclusions. With a comparable total dose of NSAIDs taking for back pain, changes in glomerular and tubular renal function are more pronounced in patients with degenerative-dystrophic diseases of the spine than in patients with axial spondyloarthritis, which can be explained by the characteristics of NSAID intake in patients with different origin of back pain.

Толық мәтін

Рұқсат жабық

Авторлар туралы

D. Bichurina

FSBEI he Saratov State Medical University n.a. V.l. Razumovsky of RMH

Postgraduate Student at the Department of Hospital Therapy of the Medical Faculty

I. Gaydukova

FSBEI he Saratov State Medical University n.a. V.l. Razumovsky of RMH; FSBEI he North-Wester State Medical University n.a. I.I. Mechnikov of RMH

Doctor of medical Sciences, Associate Professor at the Department of Therapy and Rheumatology

A. Aparkina

FSBEI he Saratov State Medical University n.a. V.l. Razumovsky of RMH

Postgraduate Student at the Department of Hospital Therapy of the Medical Faculty

E. Khondkaryan

FSBEI he Saratov State Medical University n.a. V.l. Razumovsky of RMH

Postgraduate Student at the Department of Hospital Therapy of the Medical Faculty

A. Rebrov

FSBEI he Saratov State Medical University n.a. V.l. Razumovsky of RMH

Email: aprebrov@yandex.ru
Doctor of Medical Sciences, Professor, Head of the Department of Hospital Therapy of the Medical Faculty

Әдебиет тізімі

  1. Bakland G., Gran J.T., Nossent J.C. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011; 70(11): 1921-1925. doi: 10.1136/ard.2011.151191.
  2. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13): 1296-1305. doi: 10.1056/NEJMoa041031.
  3. Cao Y.L., Tian Z.G., Wang F., Li W.G., Cheng D.Y., Yang Y.F., Gao H.M. Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World J. Gastroenterol. 2014; 20(38): 13956-65. doi: 10.3748/wjg.v20.i38.13956.
  4. Poddubnyy D., van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012; 38(3): 601-11. doi: 10.1016/j.rdc.2012.08.005.
  5. Швецов М.Ю., Бобкова И.Н., Колина И.Б., Камышова Е.С. Хроническая болезнь почек и нефропротективная терапия. М., 2012.
  6. Мухин Н.А., Моисеев С.В., Фомин В.В. Снижение скорости клубочковой фильтрации - общепопуляционный маркер риска сердечно-сосудистых осложнений. Вестник РАМН. 2010; 12: 40-43.
  7. Michener K.H., Mitchell G.F., Noubary F., Huang N., Harris T., Andresdottir M.B., Palsson R., Gudnason V., Levey A.S. Aortic Stiffness and Kidney Disease in an Elderly Population. Am J Nephrol. 2015; 41(4-5): 320-328. doi: 10.1159/000431332.
  8. Rudwaleit M., van der Heijde D., Landewé R., Listing J., Akkoc N., Brandt J., Braun J., Chou C.T., Collantes-Estevez E., Dougados M., Huang F., Gu J., Khan M.A., Kirazli Y., Maksymowych W.P., Mielants H., Sorensen I.J., Ozgocmen S., Roussou E., Valle-Onate R., Weber U., Wei J., Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009: 68(6): 777-83. doi: 10.1136/ard.2009.108233.
  9. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F. 3rd, Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., Coresh J.A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9): 604-12.
  10. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.,2002: 312-315.
  11. White A.P., Arnold P.M., Norvell D.C., Ecker E, Fehlings M.G. Pharmacologic management of chronic low back pain: synthesis of the evidence. Spine. 2011; 36(21): 131-43. doi: 10.1097/BRS.0b013e31822f178f.
  12. Brattwall M., Turan I., Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004-2008 - a retrospective patient record review. J Pain Res. 2010: 3: 131-135.
  13. Simon L.S. Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. Arthritis Res. Ther. 2013; 15(3): S1. doi: 10.1186/ar4173.
  14. Hsu C.C., Wang H., Hsu Y.H., Chuang S.Y., Huang Y.W., Chang Y.K., Liu J.S., Hsiung C.A., Tsai H.J. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015; 66(3): 524-33. doi: 10.1161/HYPERTENSIONAHA.114.05105.
  15. Pazhayattil G.S., Shirali A.C. Drug-induced impairment of renal function. Int. J. Nephrol. Renovasc Dis. 2014; 7: 457-68. doi: 10.2147/IJNRD.S39747.
  16. Middleton R.J., Foley R.N., Hegarty J., Cheung C.M., McElduff P., Gibson J.M., Kalra P.A., O’Donoghue D.J., New J.P. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol. Dial. Transplant. 2006; 21: 88-92.
  17. Segura J., Garcia-Donair J., Praga M., Ruilope L.M. Chronic kidney disease as a situation of high added risk in hypertensive patients. J. Am. Soc. Nephrol. 2006; 17(2): 136-140. doi: 10.1093/ndt/gfi163
  18. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 2005; 45(3): S1-153.
  19. Ingrasciotta. Y., Sultana J., Giorgianni F., Caputi A.P., Arcoraci V., Tari D.U., Linguiti C., Perrotta M., Nucita A., Pellegrini F., Fontana A., Cavagna L., Santoro D., Trifiro G1. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One. 2014; 9(2): e89072. doi: 10.1371/journal.pone.0089072.
  20. Гайдукова И.З., Ребров А.П., Лебединская О.А., Полянская О.Л., Патрикеева Д.А., Апаркина А.В. Хроническая болезнь почек у пациентов с хронической болью в спине, принимающих нестероидные противовоспалительные препараты. Саратовский научно-медицинский журнал. 2016; 1: 40-44.
  21. Tsai W.C., Ou T.T., Yen J.H., Wu C.C., Tung Y.C. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015; 10(5): e0126347. doi: 10.1371/journal.pone.0126347.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>